“San Antonio Breast Cancer Symposium Highlights.” by Dr. Robert Miller, #BCSM.
The San Antonio Breast Cancer Symposium is the largest scientific meeting devoted to breast cancer, attracting national and international attention. It is attended by clinicians, researchers and advocates. “The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.”
Dr. Julie Gralow is a Breast Cancer and Global Oncology Specialist at the University of Washington and Seattle Cancer Care Alliance, and is also regular participant in the #BCSM tweet chats, attended the conference. Here are some of the studies she felt were most relevant to the breast cancer community, with her interpretation of the results.
- S1-03. Adding bevacizumab (Avastin) to chemotherapy and trastuzumab (Herceptin) for patients with HER2 positive breast cancer – “BETH” trial [Article link: http://ascopost.com/ViewNews.aspx?nid=10838]
- S5-07. Using measurements of Circulating Tumor Cells (CTCs) in blood to guide chemotherapy in metastatic breast cancer – SWOG S0500 [Article link: http://www.onclive.com/conference-coverage/sabcs-2013/Level-of-CTCs-Prognostic-But-Not-Helpful-In-Switching-Therapy-in-Metastatic-Breast-Cancer]
- S3-01. Using anastrozole to reduce the risk of a first breast cancer in postmenopausal women – IBIS-II trial [Article link: http://www.medpagetoday.com/MeetingCoverage/SABCS/43383]
- S2-02, S2-03. The role of surgical resection of the primary tumor in women presenting with metastatic breast cancer [Article link: http://www.medpagetoday.com/MeetingCoverage/SABCS/43441]
